^
Association details:
| Biomarker: | BRCA mutation |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug Class: | PARP inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells
Published date:
01/01/2021
Excerpt:
A recent clinical trial reported that PARP inhibitors are effective in treating pancreatic patients carrying BRCA mutations.
